TScan Therapeutics

An experienced group of scientists, development specialists, and other leaders driving a cutting edge platform.

Launch date

2018

Employees

Market cap

Net debt

-

Enterprise valuation

$285m (Public information from Jul 2024)

Waltham Massachusetts (HQ)

https://www.tscan.com/

https://twitter.com/tscanrx https://www.linkedin.com/company/tscan-therapeutics

View job openings

Revenues, earnings & profits over time

USD	2020	2021	2022	2023	2024	2025	2026
Revenues	0000	0000	0000	0000	0000	0000	0000
% growth	-	835 %	33 %	56 %	(16 %)	(11 %)	(19 %)
EBITDA	0000	0000	0000	0000	0000	0000	0000
% EBITDA margin	(2304 %)	(447 %)	(481 %)	(381 %)	(614 %)	(827 %)	-
Profit	0000	0000	0000	0000	0000	0000	0000
% profit margin	(2408 %)	(479 %)	(489 %)	(424 %)	(588 %)	(762 %)	(1013 %)
EV / revenue	00.0x	00.0x	00.0x	00.0x	00.0x	00.0x	00.0x
EV / EBITDA	00.0x	00.0x	00.0x	00.0x	00.0x	00.0x	00.0x
R&D budget	0000	0000	0000	0000	0000	0000	0000
R&D % of revenue	1896 %	443 %	442 %	419 %	-	-	-

Get premium to view all results

Date	Investors	Amount	Round
-	investor investor	$0.0	round
Jan 2020	investor investor investor investor	$0.0	round
Jan 2021	investor investor investor investor investor investor investor	$0.0	round
Jul 2021	N/A	$0.0	round
Sep 2022	investor	$0.0	round
May 2023	N/A	$0.0	round
Apr 2024*	N/A	$150m	Post IPO Equity
Total Funding		000k

Tech stackLearn more about the technologies and tools that this company uses.